Company: JUNS
Filing Date: 2025-10-27
Form Type: 8-K
Source: 0001493152-25-019783
Chunk: 6

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-10-27
Form: 8-K
Item: Item 1.01
Chunk 6
---
 for the treatment of Parkinson’s Disease and to accelerate direct-to-consumer
marketing and sales growth of its recently launched nutritional product line Nugevia. com, as well as for working capital and other general
corporate purposes.

Under
the applicable Nasdaq rules, in no event may the Company issue to Yorkville under the SEPA or upon conversion of the Convertible Notes,
collectively, more than 7,180,504 shares of Common Stock, which number of shares is equal to 19.99% of the shares of Common Stock outstanding
immediately prior to the execution of the SEPA (the “ Exchange Cap”), unless the Company obtains the requisite stockholder
approval to issue shares of Common Stock in excess of the Exchange Cap to Yorkville under the SEPA and upon conversion of the Convertible
Notes in accordance with applicable Nasdaq rules. At the upcoming 2025 annual meeting of the Company’s stockholders to be held
on December 19, 2025 (the “2025 Annual Stockholders’ Meeting”), among other things, the Company will seek the requisite
stockholder approval in accordance with Rule 5635(d) of the Nasdaq Listing Rules (in addition to the requisite stockholder approval under Nasdaq Listing
Rule 5635(b)) to issue and sell shares of Common Stock in excess of the 7,180,504
share Exchange Cap referred to above to Yorkville under the SEPA and upon conversion of the Convertible Notes. Accordingly, if such requisite
stockholder approval is obtained at the 2025 Annual Stockholders’ Meeting, the Company would be able to issue and sell to Yorkville
in Advances under the SEPA as many shares of Common Stock as will be necessary for the Company to obtain the entire $20.0 million aggregate
purchase commitment made by Yorkville under the SEPA, which includes amounts that are used as Advance Repayments of outstanding amounts
under the Convertible Notes, and as many shares of Common Stock as will be necessary to enable Yorkville to convert all outstanding amounts
under the Convertible Notes that Yorkville elects to convert into shares of Common Stock under the terms of the Convertible Notes, in
each case, without any further aggregate share issuance limitations under Nasdaq rules. However, the 7,180,504 share Exchange Cap will
continue to limit issuances and sales of Common Stock by the Company to Yorkville under the SEPA and upon conversion of the Convertible
Notes, unless and until the Company